The corporate venture arm of a bank has a €250M evergreen fund, with about half of their investments in the life sciences. The firm invests primarily during series A-B rounds, but will occasionally invest in seed-stage companies as well, and will follow on in subsequent rounds. The firm invests in medical device, diagnostics and digital health companies, and can invest throughout Europe, but focuses mostly in France. The firm will invest anywhere from €1-20M.
The firm invests in medical devices, diagnostics and digital health technologies. Generally, the firm does not invest in therapeutics companies, nor companies in clinical stages. The firm will usually not invest in companies before they have earned their CE mark, and is generally opportunistic to indication.
The firm will only lead or co-lead investments, and always takes a board seat after investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment